Severity of gastric mucosal atrophy affects the healing speed of post-endoscopic submucosal dissection ulcers

Table 1 Characteristics of enrolled patients with gastric tumor

Parameter
Number	132
Age (yr)	71.0 ± 8.6
Gender (male/female)	100/32 (75.8%/34.2%)
H. pylori status (positive/negative)	68/64 (51.5%/48.5%)
Anti-coagulant administration (+/-)	22/110 (16.7%/83.3%)
Acid suppressant post-ESD (lansoprazole/vonoprazan)	97/35 (73.5%/26.5%)
CYP2C19 genotype (EM/IM/PM)	40/51/22 (35.4%/45.1%/19.5%)
Endoscopic background of gastric mucosa
Atrophy (Kyoto A0+A1/Kyoto A2)	20/112 (15.2%/84.8%)
Intestinal metaplasia (none + mild/severe)	72/55 (56.7%/43.3%)
Diffuse redness (none/mild/severe)	65/62 (51.2%/48.8%)
Tumor
Types (adenoma/cancer)	16/116 (12.1%/87.9%)
Depth (mucosa/submucosa)	118/14 (89.4%/10.6%)
Location of tumors (upper/middle/lower third)	15/67/50 (11.4%/50.8%/37.8%)
ESD
Mean procedure time (min)	76.4 ± 56.7
Mean resected ulcer area (mm2)	671.9 ± 720.9
ESD-induced ulcer area
Reduction at 4 wk	90.4% ± 10.7%
Mean ulcer area at 4 wk (mm2)	71.3 ± 135.6
Reduction at 8 wk	99.8% ± 0.6%
Mean ulcer area at 8 wk (mm2)	2.8 ± 15.6

EM: Extensive metabolizer of CYP2C19; ESD: Endoscopic submucosal dissection; IM: Intermediate metabolizer of CYP2C19; PM: Poor metabolizer of CYP2C19.